EBITDA Margin % is calculated as EBITDA divided by its Revenue. 10x Genomics's EBITDA for the
three
months ended in Mar. 2026 was MXN-93 Mil. 10x Genomics's Revenue for the
three
months ended in Mar. 2026 was MXN2,720 Mil. Therefore, 10x Genomics's EBITDA margin for the quarter that ended in Mar. 2026 was -3.40%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
10x Genomics EBITDA Margin % Related Terms
10x Genomics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for 10x Genomics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:TXG vs WAY, DOCS, HNGE: EBITDA Margin % Comparison
For the Health Information Services subindustry, 10x Genomics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
10x Genomics EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, 10x Genomics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where 10x Genomics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
10x Genomics (MEX:TXG) has a EBITDA Margin % of -3.40% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on 10x Genomics and its competitors. According to the industry distribution chart, 10x Genomics ranks #281 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 42.1%.
Is 10x Genomics' EBITDA Margin % too high?
10x Genomics' current EBITDA Margin % is -3.40%. Based on the distribution chart, 10x Genomics ranks #281 out of 668 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, 10x Genomics has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does 10x Genomics' EBITDA Margin % compare to WAY and DOCS?
According to the Healthcare Providers & Services industry distribution chart, 10x Genomics ranks #281 out of 668 companies for EBITDA Margin %. This puts 10x Genomics in the upper half of its industry. The industry median EBITDA Margin % is 10.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on 10x Genomics and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 10x Genomics's current EBITDA Margin % is -3.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 10x Genomics stock overvalued right now?
10x Genomics (MEX:TXG) has a current EBITDA Margin % of -3.40%. The stock's GF Value™ is MXN200.14, compared to a current price of MXN335.54 — trading 67.7% above its estimated fair value. The current EBITDA Margin % is -3.40%. 10x Genomics' overall GF Score™ is 68/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For 10x Genomics (MEX:TXG), the current EBITDA Margin % is -3.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 10x Genomics (MEX:TXG) Overvalued in 2026?
Based on GuruFocus' analysis, 10x Genomics stock appears to be overvalued.
The current stock price of MXN335.54 is trading 67.7% above its estimated GF Value™ of MXN200.14.
Key valuation signals for MEX:TXG:
EBITDA Margin %: -3.40%
GF Value™: MXN200.14 vs. price of MXN335.54 (67.7% above fair value)
No single metric tells the full story. See the MEX:TXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
68GF Score
Get the complete analysis for MEX:TXG
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:TXG has been successfully added to your 
